 Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with companys VLP platform Phase 1 study of IVX-A12 a bivalent of IVX-121 for RSV and IVX-241 for hMPV progressing and on track for topline results in mid-2023 IVX-A12 Phase 2 initiation ... The post Icosavax Provides Corporate Update and Anticipated Milestones for 2023 appeared first on ForexTV... 